trending Market Intelligence /marketintelligence/en/news-insights/trending/FzSH_PKWGtQvINtQfJydJg2 content esgSubNav
In This List

Health Sciences becomes Immunovant at closure of $395M acquisition

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Health Sciences becomes Immunovant at closure of $395M acquisition

Immunovant Inc., formerly called Health Sciences Acquisitions Corp., has closed its acquisition of Immunovant Sciences in a deal valued at about $395 million.

The merger, announced in October, makes the original Immunovant Sciences a wholly owned subsidiary of the former Health Sciences, the combined company adopting the name Immunovant.

Shareholders of Health Sciences approved the deal at a Dec. 16 meeting, and the new company will trade under the symbol IMVT on Nasdaq.

Immunovant specializes in autoimmune diseases and is developing the drug IMVT-1401 with its partner, HanAll Biopharma.